Market Research Report
Myasthenia Gravis - Pipeline Review, H2 2020
|Myasthenia Gravis - Pipeline Review, H2 2020|
Published: July 31, 2020
Global Markets Direct
Content info: 254 Pages
Delivery time: 1-2 business days
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Myasthenia Gravis - Pipeline Review, H2 2020, provides an overview of the Myasthenia Gravis (Immunology) pipeline landscape.
Myasthenia gravis is autoimmune neuromuscular disease characterized by weakness and rapid fatigue of any of the muscles under voluntary control. Symptoms include drooping of one or both eyelids, diplopia and difficulty swallowing, chewing and speaking. Treatment includes immunosuppressants, corticosteroids and surgery.
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Myasthenia Gravis - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Myasthenia Gravis (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Myasthenia Gravis (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Myasthenia Gravis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 7, 8, 7, 2, 15 and 2 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 1 molecules, respectively.
Myasthenia Gravis (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.